Shunsuke Yamamoto

Shunsuke Yamamoto

Auto-generated profile, based on publicly available information

Shunsuke Yamamoto

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
KHKiwamu Hatakeyama
Kiwamu Hatakeyama
YKYoshikane Kikushige
Yoshikane Kikushige
DIDaisuke Ishihara
Daisuke Ishihara
SYShunsuke Yamamoto
Shunsuke Yamamoto
GKGentaro Kawano
Gentaro Kawano
KAKoichi Akashi
Koichi Akashi
Immunomodulatory drugs (IMiDs) are key drugs for treating multiple myeloma and myelodysplastic syndrome with chromosome 5q deletion. IMiDs exert their pleiotropic effects through the interaction between cell-specific substrates and cereblon, a substrate receptor of the E3 ubiquitin ligase complex. Thus, identification of cell-specific substrates is important for understanding the effects of IMiDs. IMiDs increase the risk of thromboembolism, which sometimes results in fatal clinical outcomes. In this study, we sought to clarify the molecular mechanisms underlying IMiDs-induced thrombosis. We investigated cereblon substrates in human megakaryocytes using liquid chromatography–mass spectrometry and found that thrombospondin-1 (THBS-1), which is an inhibitor of a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13, functions as an endogenous substrate in human megakaryocytes. IMiDs inhibited the proteasomal degradation of THBS-1 by impairing the recruitment of cereblon to THBS-1, leading to aberrant accumulation of THBS-1. We observed a significant increase in THBS-1 in peripheral blood mononuclear cells as well as larger von Willebrand factor multimers in the plasma of patients with myeloma, who were treated with IMiDs. These results collectively suggest that THBS-1 represents an endogenous substrate of cereblon. This pairing is disrupted by IMiDs, and the aberrant accumulation of THBS-1 plays an important role in the pathogenesis of IMiDs-induced thromboembolism.

25 January 2024 in Blood
Verified
Journal Article
Closed access
PDF file
SYShunsuke Yamamoto
Shunsuke Yamamoto
MSMasafumi Sanefuji
Masafumi Sanefuji
MSMaya Suzuki
Maya Suzuki
YSYuri Sonoda
Yuri Sonoda
NHNorio Hamada
Norio Hamada
SOShouichi Ohga
Shouichi Ohga
Occupational exposure to medical agents and ionizing radiation has been suggested as a possible risk factor for childhood cancer. However, the relationship between such exposure and pediatric malignant neoplasms has not yet been comprehensively studied. This cohort study aimed to investigate the association between parental occupational exposure to hazardous medical agents or ionizing radiation and the risk of childhood cancer in offspring. Data from a large birth cohort in Japan, which included 104 062 fetuses, were analyzed. The primary outcome was the development of leukemia or brain tumors diagnosed by community physicians during the first 3 years after birth. Exposure factors were medical agents, including anticancer agents, ionizing radiation, and anesthetics, handled by mothers during pregnancy or by fathers for 3 months before conception. The incidence of leukemia, but not of brain tumors, was higher in mothers exposed to anticancer drugs. Multivariable regression analysis showed that maternal exposure to anticancer drugs was associated with an increased risk of leukemia in offspring older than 1 year (adjusted relative risk, 7.99 [95% confidence interval, 1.98-32.3]). Detailed information obtained from medical certificates of patients with identified leukemia revealed no infant leukemia but acute lymphoblastic leukemias in the exposed group. Our findings suggest that maternal occupational exposure to anticancer drugs may be a potential risk factor for acute lymphoblastic leukemia in offspring older than 1 year. Effective prevention methods may be necessary to prevent maternal exposure to anticancer drugs and to reduce the risk of childhood malignant neoplasms.

17 September 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
HGHironori Goto
Hironori Goto
UOUtako Oba
Utako Oba
TUTamaki Ueda
Tamaki Ueda
SYShunsuke Yamamoto
Shunsuke Yamamoto
MIMasataka Inoue
Masataka Inoue
SOShouichi Ohga
Shouichi Ohga
Background: Veno‐occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life‐threatening complications of hematopoietic cell transplantation (HCT). Methods: We studied the impact of early defibrotide (DF) therapy on the outcomes of pediatric patients with VOD/SOS after transplantation, focusing on recent immunotherapies. A total of 111 pediatric patients who underwent HCT for malignant disease between February 2017 and March 2023 at Kyushu University Hospital were included. Results: Among 111 patients of less than 20 years of age who underwent HCT for malignancy at a single institution between 2017 and 2023, VOD/SOS occurred in 25 (23%) patients. VOD/SOS developed more frequently in the post‐DF era (2020–2023, n = 58) than in the pre‐DF era (31% vs. 13%, p  = .04). The proportion of patients with relapsed/refractory acute lymphoblastic leukemia (ALL) was higher in the post‐DF era than in the pre‐DF era (44% vs. 8%, p  = .04). Early DF therapy that was started at two European Society for Blood and Marrow Transplantation diagnostic criteria reduced the severity of VOD/SOS ( p  < .01) in comparison to non‐early therapy started at less than two criteria. A multivariate analysis indicated that a history of cytokine release syndrome (odds ratio [OR] = 10.4, p  = .01) and juvenile myelomonocytic leukemia (OR = 8.98, p  = .04), but not an endothelial activation and stress index (EASIX) score of greater than 0.85, were independent risk factors for VOD/SOS. Conclusions: Early DF therapy improves the severity and survival outcomes of post‐transplant VOD/SOS in children. However, its incidence is increasing in the era of immunotherapy for progressive diseases.

12 February 2026 in Blood
Verified
Journal Article
Open access
GKGentaro Kawano
Gentaro Kawano
RIRiichiro Ikeda
Riichiro Ikeda
DIDaisuke Ishihara
Daisuke Ishihara
TSTakahiro Shima
Takahiro Shima
TSTeppei Sakoda
Teppei Sakoda
YKYoshikane Kikushige
Yoshikane Kikushige
Therapy resistance in acute myeloid leukemia (AML) remains a major clinical obstacle, particularly because of the persistence of leukemia stem cells (LSC) capable of metabolic adaptation. Although venetoclax (Ven) inhibits oxidative phosphorylation (OXPHOS), we found that Ven-resistant LSC undergo glycolytic reprogramming to bypass OXPHOS inhibition. This metabolic shift is supported by enhanced ribosome biogenesis, which is sustained by upregulated de novo guanine nucleotide biosynthesis. Abundant guanine nucleotides suppress the impaired ribosome biogenesis checkpoint (IRBC), leading to TP53 destabilization and persistent MYC expression. The inhibition of inosine monophosphate dehydrogenases (IMPDH1/2) depletes guanine nucleotides, activates IRBC, stabilizes TP53, represses MYC, and impairs the metabolic shift to glycolysis. This metabolic rewiring disrupts LSC stemness and suppresses the reconstitution of human AML cells in xenotransplantation experiments. Notably, the suppression of LSC stemness was observed regardless of Ven resistance or the TP53 mutational status of AML cells. These findings reveal that mutation-independent TP53 inactivation is involved in resistant AML and suggest that targeting guanine nucleotide biosynthesis may offer a clinically actionable strategy to eradicate therapy-resistant LSC.

21 May 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SYShunsuke Yamamoto
Shunsuke Yamamoto
YKYuhki Koga
Yuhki Koga
HOHiroaki Ono
Hiroaki Ono
HGHironori Goto
Hironori Goto
NHNobuhiro Hata
Nobuhiro Hata
SOShouichi Ohga
Shouichi Ohga

16 January 2022
Verified
Conference Paper
Closed access
SYShunsuke Yamamoto
Shunsuke Yamamoto
KTKohei Takegami
Kohei Takegami
Haruichi KanayaHaruichi Kanaya
Haruichi Kanaya
This paper presents the performance optimization of a slot antenna using Bayesian Optimization (BO). BO is an optimization technique that can obtain accurate results in a short time with a small amount of data. Two slot antennas with a simple structure for 5GHz-band are designed. The one is the reference slot antenna, which is designed by EM simulation without BO, and the other is the optimized slot antenna which is optimized using BO from the reference slot antenna. One design parameter is optimized to ensure that the optimal solution is obtained. Both the reference slot antenna and the optimized slot antenna are fabricated and tested. EM simulated and measured results have good agreement. As a consequence, the optimized slot antenna provided better antenna characteristics such as reflection coefficient than those of the reference slot antenna. Compared with another optimization technique which is the parametric analysis of the EM simulator, BO achieved reducing the number of EM simulations drastically to find the optimal value.